SBIR/STTR Research Award

Non-invasive delivery of skin-targeted tetanus vaccines

Award identifier 1f58547211ce2b453c053c693e992a0e7d992d447703b548dc2e79337ba60b68Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$0

Program and phase

STTR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
VAXIN INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION: (Adapted from Applicant's Abstract) A major limitation with the contemporary vaccination program as a preventative measure against tetanus is the encumbrance associated with multiple needle-dependent injections. Our aim is to develop a simple method for the delivery of tetanus vaccines by topical application of an adenovirus-vectored vaccine patch. The hypothesis is that the expression of the tetanus toxin C-fragment (tetC) in the outer layer of skin can induce a systemic immune response against the toxin molecule. We have demonstrated that a protective immune response against live Clostridium tetani infection could be elicited in mice by a single topical application of a patch containing an adenovirus vector encoding tetC. These studies will further develop the vectored vaccine patch, and specifically determine whether this novel approach for the delivery of vaccines can mobilize the immune repertoire against tetanus in humans. In this project, the potential for a vectored vaccine patch to elicit a protective immune response against tetanus in animals with pre-existing immunity to adenovirus will be investigated. A new generation of adenovirus vectors with reduced immunogenicity as well as enhanced transduction efficiency for the outer layer of skin will be developed as novel vaccine carriers. Efficacy of NIVS will be compared to those induced by other means. The interaction between vectors and the host will be studied by determining the fate of vector DNA. A Phase I human clinical trial for evaluating the safety of a vectored vaccine patch will be conducted. The overall goal of these experiments is to determine whether tetanus vaccines can be effectively and safely delivered by a skin patch that requires a lower level of skill in a needle-free manner. PROPOSED COMMERCIAL APPLICATION: Non-invasive vaccination onto the skin may boost vaccine coverage against tetanus because the procedure is simple, effective, painless, and safe, The development may also make vaccination programs less dependent upon medical resources.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.